These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 26590293)

  • 1. Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial.
    Ng KH; Shestakovska O; Connolly SJ; Eikelboom JW; Avezum A; Diaz R; Lanas F; Yusuf S; Hart RG
    Age Ageing; 2016 Jan; 45(1):77-83. PubMed ID: 26590293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial.
    Flaker GC; Eikelboom JW; Shestakovska O; Connolly SJ; Kaatz S; Budaj A; Husted S; Yusuf S; Lip GY; Hart RG
    Stroke; 2012 Dec; 43(12):3291-7. PubMed ID: 23033347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
    Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial.
    Diener HC; Eikelboom J; Connolly SJ; Joyner CD; Hart RG; Lip GY; O'Donnell M; Hohnloser SH; Hankey GJ; Shestakovska O; Yusuf S;
    Lancet Neurol; 2012 Mar; 11(3):225-31. PubMed ID: 22305462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.
    Yates SW
    Hosp Pract (1995); 2011 Oct; 39(4):7-16. PubMed ID: 22056819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease.
    Eikelboom JW; Connolly SJ; Gao P; Paolasso E; De Caterina R; Husted S; O'Donnell M; Yusuf S; Hart RG
    J Stroke Cerebrovasc Dis; 2012 Aug; 21(6):429-35. PubMed ID: 22818021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients.
    Lip GY; Lanitis T; Mardekian J; Kongnakorn T; Phatak H; Dorian P
    Stroke; 2015 Oct; 46(10):2830-7. PubMed ID: 26316345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
    Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
    Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apixaban in patients with atrial fibrillation.
    Connolly SJ; Eikelboom J; Joyner C; Diener HC; Hart R; Golitsyn S; Flaker G; Avezum A; Hohnloser SH; Diaz R; Talajic M; Zhu J; Pais P; Budaj A; Parkhomenko A; Jansky P; Commerford P; Tan RS; Sim KH; Lewis BS; Van Mieghem W; Lip GY; Kim JH; Lanas-Zanetti F; Gonzalez-Hermosillo A; Dans AL; Munawar M; O'Donnell M; Lawrence J; Lewis G; Afzal R; Yusuf S;
    N Engl J Med; 2011 Mar; 364(9):806-17. PubMed ID: 21309657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modification of outcomes with aspirin or apixaban in relation to female and male sex in patients with atrial fibrillation: a secondary analysis of the AVERROES study.
    Lip GY; Eikelboom J; Yusuf S; Shestakovska O; Hart RG; Connolly S;
    Stroke; 2014 Jul; 45(7):2127-30. PubMed ID: 24916911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial.
    van Nieuwenhuizen KM; van der Worp HB; Algra A; Kappelle LJ; Rinkel GJ; van Gelder IC; Schutgens RE; Klijn CJ;
    Trials; 2015 Sep; 16():393. PubMed ID: 26340977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.
    Eikelboom JW; O'Donnell M; Yusuf S; Diaz R; Flaker G; Hart R; Hohnloser S; Joyner C; Lawrence J; Pais P; Pogue J; Synhorst D; Connolly SJ
    Am Heart J; 2010 Mar; 159(3):348-353.e1. PubMed ID: 20211294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial.
    Hu PT; Lopes RD; Stevens SR; Wallentin L; Thomas L; Alexander JH; Hanna M; Lewis BS; Verheugt FW; Granger CB; Jones WS
    J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28096100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial.
    Coppens M; Synhorst D; Eikelboom JW; Yusuf S; Shestakovska O; Connolly SJ
    Eur Heart J; 2014 Jul; 35(28):1856-63. PubMed ID: 24569032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of apixaban versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation in Belgium.
    Kongnakorn T; Lanitis T; Lieven A; Thijs V; Marbaix S
    Clin Drug Investig; 2014 Oct; 34(10):709-21. PubMed ID: 25164005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study.
    Lip GY; Connolly S; Yusuf S; Shestakovska O; Flaker G; Hart R; Lanas F; Xavier D; Eikelboom J;
    Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):31-8. PubMed ID: 23390125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia.
    Hersi AS; Osenenko KM; Kherraf SA; Aziz AA; Sambrook RJ
    Ann Saudi Med; 2019; 39(4):265-278. PubMed ID: 31381381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight.
    Hohnloser SH; Fudim M; Alexander JH; Wojdyla DM; Ezekowitz JA; Hanna M; Atar D; Hijazi Z; Bahit MC; Al-Khatib SM; Lopez-Sendon JL; Wallentin L; Granger CB; Lopes RD
    Circulation; 2019 May; 139(20):2292-2300. PubMed ID: 30773022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.
    Athanasakis K; Boubouchairopoulou N; Karampli E; Tarantilis F; Savvari P; Bilitou A; Kyriopoulos J
    Am J Cardiovasc Drugs; 2017 Apr; 17(2):123-133. PubMed ID: 27882517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.